← Back

StemRIM Inc.

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.

Price · split & dividend adjusted
News & notes moving 4599.JP
4599.JP

Mitsui Matsushima Holdings raises earnings forecast and dividend, makes Sanyo a subsidiary

Mitsui Matsushima Holdings has revised upward its consolidated earnings forecast for the fiscal year ending March 2027 and announced an increase in its annual dividend. At the same time, it will make Sanyo, a manufacturer and seller of cotton swabs and cotton balls, a subsidiary. Separately, OBC reported a sharp profit increase for the first quarter of the fiscal year ending March 2027, while CDS and Toho Remac revised downward their consolidated earnings forecasts for the cumulative second quarter of the fiscal year ending December 2026. Bronco Billy announced its financial results and revised its earnings and dividend forecasts, and Stemrim reported that a patent for its regenerative medicine Redasemtide related to cartilage disease has been registered in Mexico. Tsubota Laboratory achieved a milestone upon submission of the clinical study report for TLG-001, confirming receipt of payment, Mitra established a wholly owned subsidiary specializing in inheritance-related services, and AZC Maruwa introduced a new shareholder benefit program.
ウエルスアドバイザー·35dRead more ▾